“Former Celgene shareholders filed suit against BMS back in...

“Former Celgene shareholders filed suit against BMS back in June, accusing the drugmaker of “blatant misconduct” in allegedly delaying development of CAR-T lymphoma therapy Breyanzi. At the time of the original filing, BMS declined to comment.Now, a slate of confidential witnesses have come forward to detail just how Bristol Myers dropped the ball. In a new filing, lawyers for the plaintiffs laid out the drugmaker’s myriad opportunities to rectify the situation before it was too late. BMS would have owed former Celgene shareholders $6.4 billion if it scored FDA approval for three new drugs—Zeposia, Breyanzi and Abecma—each by a particular deadline. When Breyanzi, also known as liso-cel, failed to make it past the FDA finish line by Dec. 31, 2020, the CVR became worthless.”



@JB1975

Shame you didn’t do your research properly….if you did you would have noticed that the issues raised regarding Lonza and BMS had a little twist….not that you were to know when finding one potentially tainted example to use against this Company. Let me update you on the storyline with reference to your own quoted source material .

https://www.fiercepharma.com/pharma/major-blunder-ex-staffers-blast-bristol-myers-squibb-s-handling-breyanzi-approval-latest-cvr

So the six month delay at BMS allegedly saved them billions of contingent payments ? Note this was a whistle blower case with witnesses for the lawsuit coming from within the company….

Sad that you spend so much time disparaging such a desperately needed therapy for children who have up to 90% mortality rates for severe forms of this disease. I acknowledge your right to do so, but my stomach churns at the thought of such behaviour. This is an unmet need for goodness sake. Might have something to do with the fact that if a seven year exclusive license is granted for this orphan indication, the claims of another listed Aussie early stage biotech reaching commerciality for its steroid refractory treatment for aGVHD will be pretty much grounded in my opinion. I still believe there is long term value for them in large volume low price applications like for such as diabetic foot ulcers, but they are deluding themselves over aGVHD . OP



Please do not rely on the accuracy of any facts or opinions (including statements made in referenced publications) when making an investment decision.